{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:09:25Z","timestamp":1761487765019},"reference-count":56,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,12,19]],"date-time":"2006-12-19T00:00:00Z","timestamp":1166486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2007,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p> <jats:italic>Objective:<\/jats:italic>\u2002Patients with hematologic malignancies are at substantial risk of developing invasive fungal infections (IFI) that are associated with substantial morbidity and mortality. This article reviews the epidemiology, risk factors, and efficacy of antifungal prophylaxis in patients with hematologic malignancies. <jats:italic>Methods:<\/jats:italic>\u2002A PubMed search was conducted to identify relevant studies with special emphasis on meta\u2010analyses and direct comparisons between antifungal agents. <jats:italic>Results:<\/jats:italic>\u2002The epidemiology of IFI has changed substantially in recent years with <jats:italic>Candida albicans<\/jats:italic> becoming less common owing to the widespread prophylactic use of azole antifungals. Invasive aspergillosis, fusariosis, and zygomycosis have increased in frequency. This change is at least partly related to the use of broad\u2010spectrum antifungal agents, either as prophylaxis or as empirical treatment. Other risk factors for IFI include prior fungal exposure, immunosuppression, underlying disease, graft\u2010vs.\u2010host disease, and organ dysfunction. Inconsistent results have been reported in studies evaluating the efficacy of antifungal prophylaxis in patients at risk of IFI. Meta\u2010analyses found that antifungals, such as fluconazole and itraconazole, are effective in decreasing IFI and IFI\u2010related mortality, primarily owing to yeast infections in patients with more severe immunosuppression (i.e. patients undergoing bone marrow transplantation), but do not decrease the overall mortality. The European Conference on Infections in Leukemia (ECIL) guidelines currently recommend fluconazole (AI, ie. strongly recommended, based on at least 1 well\u2010executed, randomized trial) and itraconazole (BI, ie. generally recommended, based on at least 1 well\u2010executed, randomized trial) in allogeneic transplant recipients. Posaconazole, a triazole antifungal, has been recently shown to decrease IFI incidence and overall mortality in some high\u2010risk patients compared with standard azoles. Based on preliminary data, a provisional AI ECIL recommendation has been given. <jats:italic>Conclusions:<\/jats:italic>\u2002Because of the substantial morbidity and mortality associated with IFI, there is a need to accurately define patient groups at greatest risk of IFI and, when appropriate, to initiate effective antifungal prophylaxis.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2006.00805.x","type":"journal-article","created":{"date-parts":[[2007,1,23]],"date-time":"2007-01-23T11:33:16Z","timestamp":1169551996000},"page":"275-282","source":"Crossref","is-referenced-by-count":55,"title":["Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies"],"prefix":"10.1111","volume":"78","author":[{"given":"Johan","family":"Maertens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,12,19]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/41.suppl_4.1"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2003.1.438"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.2.361"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02014.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.6.1545"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.6.2055"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0773-3"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki221"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704423"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1496"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/339202"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cco.0000152975.65477.7c"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001432-200212000-00003"},{"key":"e_1_2_7_15_2","first-page":"9","article-title":"Invasive Candida infections: the changing epidemiology","volume":"18","author":"Marr KA","year":"2004","journal-title":"Oncology (Huntingt)"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/342300"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.01.002"},{"key":"e_1_2_7_18_2","unstructured":"HannaH KontoyiannisD BuddineniJ BoktourM AntoniadouA HachemR RaadI.The changing epidemiology of candidemia in hematologic malignancy (HM):Candida glabrataandCandida kruseiare the leading causes of fungemia [abstract M989]. Presented at: 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Washington DC December 16\u201319 2005 pp428."},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh532"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2005.01.001"},{"key":"e_1_2_7_21_2","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM\u20102004 study","volume":"91","author":"Pagano L","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/428780"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21847"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/322606"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03259.x"},{"key":"e_1_2_7_26_2","first-page":"974","article-title":"Prevention of fungal infections in the immunocompromised host","volume":"4","author":"Mahfouz T","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00030-8"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(02)00035-1"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04794.x"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441415"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.01.054"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10610"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20001001)89:7<1611::AID-CNCR27>3.0.CO;2-B"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.052"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01465.x"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki440"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705418"},{"key":"e_1_2_7_38_2","first-page":"512","article-title":"Efficacy of different prophylactic antifungal regimens in bone marrow transplantation","volume":"80","author":"Annaloro C","year":"1995","journal-title":"Haematologica"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.52.5.376"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2644"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-9-200305060-00006"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05727.x"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1086\/422312"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.143-147.2006"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11094"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702233"},{"key":"e_1_2_7_47_2","volume-title":"European guidelines for primary antifungal prophylaxis in leukemia patients","author":"Maertens J","year":"2006"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1356"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2004.00167.x"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565110-00007"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00163-06"},{"key":"e_1_2_7_52_2","doi-asserted-by":"crossref","first-page":"524A","DOI":"10.1182\/blood.V106.11.1844.1844","article-title":"Posaconazole vs standard azole (FLU\/ITRA) therapy for prophylaxis of invasive fungal infections (IFIs) among high\u2010risk neutropenic patients: results of a randomized, multicenter trial [abstract]","volume":"106","author":"Cornely O","year":"2005","journal-title":"Blood"},{"key":"e_1_2_7_53_2","volume-title":"Mortality in patients at high risk for invasive fungal infection: effect of posaconazole prophylaxis","author":"Cornely OA","year":"2006"},{"key":"e_1_2_7_54_2","first-page":"S29","article-title":"Prophylaxis of invasive fungal infection with posaconazole or standard azoles (fluconazole\/itraconazole) in patients with acute myelogenous leukemia or myelodysplastic syndrome and chemotherapy\u2010induced neutropenia: results of a randomized multicenter trial [abstract]","volume":"37","author":"Maertens J","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_7_55_2","volume-title":"Posaconazole as prophylaxis for invasive fungal infections in high\u2010risk patients: efficacy and safety results from 2 clinical trials","author":"Maertens J","year":"2006"},{"key":"e_1_2_7_56_2","first-page":"S163","article-title":"Prophylactic treatment of invasive fungal infections with posaconazole or fluconazole in allogeneic hematopoietic stem cell transplant recipients with graft\u2010versus\u2010host disease [abstract]","volume":"37","author":"Ullmann AJ","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_7_57_2","volume-title":"Posaconazole vs fluconazole for prophylaxis of invasive fungal infections in allogeneic hematopoietic stem cell transplantation recipients with graft\u2010versus\u2010host disease: a multicenter trial","author":"Ullmann AJ","year":"2005"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2006.00805.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2006.00805.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T22:12:23Z","timestamp":1696975943000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2006.00805.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12,19]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["10.1111\/j.1600-0609.2006.00805.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2006.00805.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12,19]]}}}